Flexion Therapeutics Inc  

(Public, NASDAQ:FLXN)   Watch this stock  
Find more results for Michael Merrifield�
11.03
-0.28 (-2.48%)
Real-time:   10:58AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 10.87 - 11.64
52 week 10.87 - 30.37
Open 11.06
Vol / Avg. 50,651.00/126,522.00
Mkt cap 237.58M
P/E     -
Div/yield     -
EPS -2.00
Shares 21.54M
Beta     -
Inst. own 114%
Mar 21, 2016
Q4 2015 Flexion Therapeutics Inc Earnings Release (Estimated) Add to calendar
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -33.21% -31.74%
Return on average equity -37.01% -68.08%
Employees 29 -
CDP Score - -

Address

10 Mall Rd Ste 301
BURLINGTON, MA 01803-4121
United States - Map
+1-781-3057777 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Flexion Therapeutics, Inc. is a specialty pharmaceutical company focused on the development and commercialization of injectable pain therapies. The Company is also focused on anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions, such as osteoarthritis (OA), a type of degenerative arthritis. The Company's portfolio of product candidates addresses the OA pain treatment spectrum, from moderate to severe pain. The Company's products include FX006, which is indicated for front line intra-articular (IA) therapy for patients with moderate to severe OA pain; FX007, which is indicated for post-operative pain, and FX005, which is indicated for end-stage OA pain. The Company is conducting a pivotal Phase IIb clinical trial of FX006. The Company is conducting preclinical local pharmacology and toxicology experiments of FX007. FX005 has completed its Phase IIa trials.

Officers and directors

Patrick J. Mahaffy Chairman of the Board
Age: 52
Bio & Compensation  - Reuters
Michael D. Clayman M.D. President, Chief Executive Officer, Co-Founder, Director
Age: 62
Bio & Compensation  - Reuters
Neil Bodick MD, PhD Chief Medical Officer & Co-Founder
Age: 68
Bio & Compensation  - Reuters
Frederick W. Driscoll Chief Financial Officer
Age: 64
Bio & Compensation  - Reuters
Scott A. Canute Independent Director
Age: 54
Bio & Compensation  - Reuters
Samuel D. Colella MBA Independent Director
Age: 75
Bio & Compensation  - Reuters
Heath Lukatch Ph.D. Independent Director
Age: 47
Bio & Compensation  - Reuters
Sandesh Mahatme Independent Director
Age: 49
Bio & Compensation  - Reuters
Ann Merrifield Independent Director
Age: 64
Bio & Compensation  - Reuters